Citigroup Inc. Sells 182,603 Shares of Haleon PLC Sponsored ADR (NYSE:HLN)

Key Points

• Citigroup Inc. has reduced its stake in Haleon PLC by 17.4%, selling 182,603 shares and ending with 868,948 shares worth approximately $8.94 million.
• Haleon has increased its semi-annual dividend to $0.0555, up from $0.05, with a yield of 190.0%.
• Analysts have mixed ratings on Haleon, with a consensus rating of "Moderate Buy" and a price target averaging $12.33, following various upgrades and downgrades.

Citigroup Inc. lessened its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 17.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 868,948 shares of the company's stock after selling 182,603 shares during the quarter. Citigroup Inc.'s holdings in Haleon were worth $8,941,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its position in shares of Haleon by 6.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,223 shares of the company's stock valued at $306,000 after acquiring an additional 1,749 shares during the last quarter. Oppenheimer & Co. Inc. lifted its position in Haleon by 11.2% in the 1st quarter. Oppenheimer & Co. Inc. now owns 25,362 shares of the company's stock worth $261,000 after buying an additional 2,564 shares during the last quarter. Concurrent Investment Advisors LLC lifted its position in Haleon by 32.9% in the 1st quarter. Concurrent Investment Advisors LLC now owns 16,363 shares of the company's stock worth $168,000 after buying an additional 4,055 shares during the last quarter. Mather Group LLC. lifted its position in Haleon by 60.7% in the 1st quarter. Mather Group LLC. now owns 9,036 shares of the company's stock worth $93,000 after buying an additional 3,413 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in Haleon by 8.8% in the 1st quarter. Farther Finance Advisors LLC now owns 12,861 shares of the company's stock worth $131,000 after buying an additional 1,041 shares during the last quarter. Institutional investors own 6.67% of the company's stock.

Haleon Stock Performance

Shares of HLN stock opened at $9.64 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. Haleon PLC Sponsored ADR has a fifty-two week low of $8.86 and a fifty-two week high of $11.42. The stock has a 50 day moving average price of $10.04 and a two-hundred day moving average price of $10.20. The company has a market capitalization of $43.30 billion, a P/E ratio of 24.72, a PEG ratio of 2.85 and a beta of 0.23.

Haleon Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Thursday, September 18th. Shareholders of record on Friday, August 15th will be given a $0.0555 dividend. The ex-dividend date is Friday, August 15th. This is an increase from Haleon's previous semi-annual dividend of $0.05. This represents a yield of 190.0%. Haleon's dividend payout ratio is presently 64.10%.

Analysts Set New Price Targets

A number of analysts recently weighed in on HLN shares. Wall Street Zen downgraded Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Morgan Stanley upgraded Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price for the company in a research report on Friday, May 9th. BNP Paribas upgraded Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 target price for the company in a research report on Tuesday, May 27th. Finally, Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Five research analysts have rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.